[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2014188201A3 - Medicaments for use in methods of treating cancers which comprise a decreased amount of hk36me - Google Patents

Medicaments for use in methods of treating cancers which comprise a decreased amount of hk36me Download PDF

Info

Publication number
WO2014188201A3
WO2014188201A3 PCT/GB2014/051577 GB2014051577W WO2014188201A3 WO 2014188201 A3 WO2014188201 A3 WO 2014188201A3 GB 2014051577 W GB2014051577 W GB 2014051577W WO 2014188201 A3 WO2014188201 A3 WO 2014188201A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
hk36me
medicaments
treating cancers
decreased amount
Prior art date
Application number
PCT/GB2014/051577
Other languages
French (fr)
Other versions
WO2014188201A2 (en
Inventor
Sophia Xiao Zhang PFISTER
Timothy C HUMPHREY
Rachel S DEEGAN
Original Assignee
Cancer Research Technology Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201309238A external-priority patent/GB201309238D0/en
Priority claimed from GB201321115A external-priority patent/GB201321115D0/en
Application filed by Cancer Research Technology Limited filed Critical Cancer Research Technology Limited
Publication of WO2014188201A2 publication Critical patent/WO2014188201A2/en
Publication of WO2014188201A3 publication Critical patent/WO2014188201A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to methods of treating cancers which comprise a decreased amount of H3K36me3. Kits for use in such methods are also provided.
PCT/GB2014/051577 2013-05-22 2014-05-22 Treatment WO2014188201A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1309238.2 2013-05-22
GB201309238A GB201309238D0 (en) 2013-05-22 2013-05-22 Treatment
GB201321115A GB201321115D0 (en) 2013-11-29 2013-11-29 Treatment
GB1321115.6 2013-11-29

Publications (2)

Publication Number Publication Date
WO2014188201A2 WO2014188201A2 (en) 2014-11-27
WO2014188201A3 true WO2014188201A3 (en) 2015-03-05

Family

ID=50829207

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2014/051577 WO2014188201A2 (en) 2013-05-22 2014-05-22 Treatment

Country Status (1)

Country Link
WO (1) WO2014188201A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016112374A2 (en) * 2015-01-09 2016-07-14 The General Hospital Corporation Treating cancer using inhibitors of ataxia-telangiectasia mutated and rad3-related (atr)
US11156599B2 (en) * 2015-03-19 2021-10-26 The Johns Hopkins University Assay for telomere length regulators

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006005462A2 (en) * 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with tyrosine kinase wee 1 (wee1)
WO2011038160A2 (en) * 2009-09-23 2011-03-31 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes expressed in cancer
US20120029062A1 (en) * 2010-08-02 2012-02-02 Gunaratne Preethi H Interior functionalized hyperbranched dendron-conjugated nanoparticles and uses thereof
WO2012074754A1 (en) * 2010-11-16 2012-06-07 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006005462A2 (en) * 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with tyrosine kinase wee 1 (wee1)
WO2011038160A2 (en) * 2009-09-23 2011-03-31 Protiva Biotherapeutics, Inc. Compositions and methods for silencing genes expressed in cancer
US20120029062A1 (en) * 2010-08-02 2012-02-02 Gunaratne Preethi H Interior functionalized hyperbranched dendron-conjugated nanoparticles and uses thereof
WO2012074754A1 (en) * 2010-11-16 2012-06-07 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ADAM M. FONTEBASSO ET AL: "Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas", ACTA NEUROPATHOLOGICA, vol. 125, no. 5, 16 February 2013 (2013-02-16), pages 659 - 669, XP055134406, ISSN: 0001-6322, DOI: 10.1007/s00401-013-1095-8 *
G. DUNS ET AL: "Histone Methyltransferase Gene SETD2 Is a Novel Tumor Suppressor Gene in Clear Cell Renal Cell Carcinoma", CANCER RESEARCH, vol. 70, no. 11, 25 May 2010 (2010-05-25), pages 4287 - 4291, XP055140431, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-10-0120 *
JENNY M. KREAHLING ET AL: "Wee1 Inhibition by MK-1775 Leads to Tumor Inhibition and Enhances Efficacy of Gemcitabine in Human Sarcomas", PLOS ONE, vol. 8, no. 3, 8 March 2013 (2013-03-08), pages e57523, XP055140781, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0057523 *
LAURA CARRASSA ET AL: "Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo", CELL CYCLE, vol. 11, no. 13, 1 July 2012 (2012-07-01), pages 2507 - 2517, XP055140308, ISSN: 1538-4101, DOI: 10.4161/cc.20899 *
LI FENG ET AL: "The Histone Mark H3K36me3 Regulates Human DNA Mismatch Repair through Its Interaction with MutS[alpha]", CELL, CELL PRESS, US, vol. 153, no. 3, 25 April 2013 (2013-04-25), pages 590 - 600, XP028589806, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2013.03.025 *
SCHMIDT CHRISTINE K ET AL: "On Your MARK, Get SET(D2), Go! H3K36me3 Primes DNA Mismatch Repair", CELL, CELL PRESS, US, vol. 153, no. 3, 17 April 2013 (2013-04-17), pages 513 - 515, XP028589821, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2013.04.018 *
THAI HUU HO ET AL: "Regulation of SETD2, a histone methyltransferase, in advanced clear cell renal cell carcinoma (ccRCC)", J CLIN ONCOL 30, 2012 (SUPPL 5; ABSTR 368), 1 February 2012 (2012-02-01), XP055140427, Retrieved from the Internet <URL:http://meetinglibrary.asco.org/print/569434> [retrieved on 20140916] *

Also Published As

Publication number Publication date
WO2014188201A2 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
EP3288382A4 (en) Methods for treating cancer
EP3092006A4 (en) Targeted therapy for small cell lung cancer
EP3076977A4 (en) Combination therapy for treating cancer
EP3027192A4 (en) Methods for the treatment of solid tumors
EP3049442A4 (en) Methods for treating hematologic cancers
EP3180010A4 (en) Combination therapy for treating cancer
EP2861256A4 (en) Compositions for treating cancer and methods for making the same
EP3060207A4 (en) Methods and compositions for treating cancer
EP2968254A4 (en) Methods of treating lung cancer
EP3280437A4 (en) Egfr-directed car therapy for glioblastoma
HK1220155A1 (en) Methods for treating cancer
EP3207162A4 (en) Combination therapy for use in cancer therapy
EP3085380A4 (en) Composition for treating prostate cancer
EP3074426A4 (en) Milling process
EP3193884A4 (en) Combination therapy for treating cancer
EP3389634A4 (en) Methods for treating cancer
EP2994148B8 (en) Cancer therapy
EP3007756A4 (en) Catheter-assisted tumor treatment
EP3213752A4 (en) Composition for treating cancer stem cells
EP3389652A4 (en) Methods for treating cancer
EP3052102A4 (en) Compositions and methods for treating cancers
EP3411073A4 (en) Combinations to treat cancer
EP3099297A4 (en) Novel methods for treating cancer
EP3004395A4 (en) Compositions and methods for treating cancer
EP3057593A4 (en) Treatment for pancreatic cancer

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14726743

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14726743

Country of ref document: EP

Kind code of ref document: A2